Zhong Yuting, Zhang Yanjun, Liu Mei, Cheng Liuquan, Yang Junlan, Li Xiru
Medical School of Chinese PLA, Beijing, China.
Department of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, China.
Ann Transl Med. 2023 Jun 30;11(9):323. doi: 10.21037/atm-22-5062. Epub 2023 Jun 13.
Five-year treatment with tamoxifen (TAM) has been the traditional standard of care for breast cancer. Organising pneumonia (OP) is a rare but significant complication of radiation therapy for breast cancer. The effect of TAM leading to OP has not yet been clearly documented.
This report describes the case of a 38-year-old female who developed progressive aggravation of round-like patchy bilateral pulmonary infiltrated with a reverse halo sign but without any clinical symptoms 5 months after TAM therapy, following breast-conserving surgery and radiotherapy (RT) for breast carcinoma. A lung biopsy was performed and revealed a histological pattern of OP. TAM therapy was discontinued, and subsequent gradual radiological improvement was observed. As there was no proof for TAM had caused the incident, TAM was re-administrated. Eight months after reinstitution of TAM, the same patchy migratory bilateral pulmonary infiltrated with reverse halo sign was found on chest CT with the patient claiming no discomforts nor any clinical symptoms. The diagnosis of TAM-related OP was made based on the exclusion of other causes and recurrence with the re-administration of TAM. The multidisciplinary team (MDT) concluded that TAM should be withdrawn and a "wait-and-see" approach was taken after a comprehensive assessment, instead of altering the medication or performing prophylactic mastectomy.
The withdrawal and rechallenge of TAM strongly suggest that it may play a role as a cofactor in the occurrence of OP after RT for breast cancer, and RT may also be a cofactor in the occurrence of OP. It is extremely important to be alerted to the possibility of OP after concurrent or sequential hormonal therapy and RT.
他莫昔芬(TAM)五年治疗一直是乳腺癌的传统标准治疗方案。机化性肺炎(OP)是乳腺癌放疗罕见但重要的并发症。TAM导致OP的影响尚未得到明确记录。
本报告描述了一名38岁女性的病例,该患者在接受乳腺癌保乳手术和放疗(RT)后5个月接受TAM治疗,出现双侧肺部圆形斑片状浸润进行性加重,伴有反晕征,但无任何临床症状。进行了肺活检,显示为OP的组织学模式。停用TAM治疗后,观察到随后影像学逐渐改善。由于没有证据表明TAM导致了该事件,因此重新给予TAM。重新使用TAM八个月后,胸部CT发现双侧肺部出现相同的斑片状游走性浸润并伴有反晕征,患者声称没有不适或任何临床症状。基于排除其他原因以及重新使用TAM后复发,做出了与TAM相关的OP的诊断。多学科团队(MDT)得出结论,在综合评估后应停用TAM并采取“观察等待”方法,而不是更换药物或进行预防性乳房切除术。
TAM的停用和重新使用强烈表明,它可能在乳腺癌放疗后OP的发生中作为辅助因素起作用,放疗也可能是OP发生的辅助因素。在同时或序贯进行激素治疗和放疗后警惕OP的可能性极为重要。